Hallek M - Search Results

1

Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.

Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH. Nicklin SA, et al. Among authors: hallek m. Mol Ther. 2001 Sep;4(3):174-81. doi: 10.1006/mthe.2001.0424. Mol Ther. 2001. PMID: 11545607 Free article.

2

Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.

White K, Büning H, Kritz A, Janicki H, McVey J, Perabo L, Murphy G, Odenthal M, Work LM, Hallek M, Nicklin SA, Baker AH. White K, et al. Among authors: hallek m. Gene Ther. 2008 Mar;15(6):443-51. doi: 10.1038/sj.gt.3303077. Epub 2007 Nov 15. Gene Ther. 2008. PMID: 18004401

3

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.

Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, Hallek M. Huttner NA, et al. Among authors: hallek m. Gene Ther. 2003 Dec;10(26):2139-47. doi: 10.1038/sj.gt.3302123. Gene Ther. 2003. PMID: 14625569

4

Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.

Hacker UT, Gerner FM, Büning H, Hutter M, Reichenspurner H, Stangl M, Hallek M. Hacker UT, et al. Among authors: hallek m. Gene Ther. 2001 Jun;8(12):966-8. doi: 10.1038/sj.gt.3301466. Gene Ther. 2001. PMID: 11426338

5

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M. Girod A, et al. Among authors: hallek m. Nat Med. 1999 Sep;5(9):1052-6. doi: 10.1038/12491. Nat Med. 1999. PMID: 10470084

6

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Wobus CE, Hügle-Dörr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Wobus CE, et al. Among authors: hallek m. J Virol. 2000 Oct;74(19):9281-93. doi: 10.1128/jvi.74.19.9281-9293.2000. J Virol. 2000. PMID: 10982375 Free PMC article.

7

[Basis of gene therapy: principles and state of development].

Hallek M, Buening H, Ried M, Hacker U, Kurzeder C, Wendtner CM. Hallek M, et al. Internist (Berl). 2001 Oct;42(10):1306-8, 1311-3. doi: 10.1007/s001080170052. Internist (Berl). 2001. PMID: 11688149 Review. German. No abstract available.

8

Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors.

Braun-Falco M, Doenecke A, Smola H, Hallek M. Braun-Falco M, et al. Among authors: hallek m. Gene Ther. 1999 Mar;6(3):432-41. doi: 10.1038/sj.gt.3300815. Gene Ther. 1999. PMID: 10435093

9

Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors.

Kofler DM, Büning H, Mayr C, Bund D, Baumert J, Hallek M, Wendtner CM. Kofler DM, et al. Among authors: hallek m. Gene Ther. 2004 Sep;11(18):1416-24. doi: 10.1038/sj.gt.3302279. Gene Ther. 2004. PMID: 15269708

10

Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.

Hellebrand E, Mautner J, Reisbach G, Nimmerjahn F, Hallek M, Mocikat R, Hammerschmidt W. Hellebrand E, et al. Among authors: hallek m. Gene Ther. 2006 Jan;13(2):150-62. doi: 10.1038/sj.gt.3302602. Gene Ther. 2006. PMID: 16136164

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

827 results

Search Page

Filters